Skip to content

Introduced in India: AI-Enhanced Kardia 12L Portable ECG Device Approved by CDSCO, by AliveCor

Portable 12-lead ECG device accurately identifies 35 heart conditions, encompassing acute myocardial infarction and cardiac ischemia, specifically meant for medical professionals

Artificial Intelligence-equipped AliveCor introduces the 12L handheld ECG system in India, approved...
Artificial Intelligence-equipped AliveCor introduces the 12L handheld ECG system in India, approved by the Central Drugs Standard Control Organization (CDSCO)

Introduced in India: AI-Enhanced Kardia 12L Portable ECG Device Approved by CDSCO, by AliveCor

In a significant funding event for the diagnostics industry, Invicta Diagnostic has secured in-principle approval from NSE Emerge for an Initial Public Offering (IPO), aiming to raise ₹28 crore. However, it's important to note that the IPO is yet to be fully approved and finalized by the stock exchange.

This latest development in the Indian diagnostics sector comes as Invicta Diagnostic plans to use the funds raised through the IPO for business expansion and growth. The exact timeline for the IPO has not been disclosed.

Meanwhile, Aarthi Scans has made a notable stride in the field with the launch of a helium-free 1.5T MRI in Bengaluru, provided by Siemens Healthineers. This innovation promises to reduce the reliance on helium, a resource in short supply, making MRI scans more accessible and sustainable.

Elsewhere in the industry, Meril has introduced MyClip, India's first Transcatheter-Edge-to-Edge Repair (TEER) system. This advancement in cardiac care technology is expected to revolutionise the treatment of mitral regurgitation, a common and often debilitating heart condition.

Outside the realm of diagnostics, FAULHABER has recently opened a new sales office in India. This move is expected to strengthen the company's presence in the Indian market, particularly in the field of precision drive technology.

Despite these exciting developments, it's worth noting that the IPO by Invicta Diagnostic is not related to any other companies or entities mentioned in this article. Additionally, the IPO is not associated with any specific type of diagnostic technology or service.

Lastly, while there have been updates to the diagnostic criteria for frontotemporal dementia, the specific names of the researchers responsible for these updates have not been disclosed in the search results.

As these developments unfold, the Indian diagnostics sector continues to show promise, with advancements in technology, funding, and treatment options. Stay tuned for more updates as these stories continue to evolve.

Read also: